Poonam A. Arora
Long/short equity, value, research analyst, biotech

Puma Biotechnology: Shares Overbought At Current Levels

Investment Conclusion. On July 22, Puma Biotechnology (NYSE:PBYI) reported data from its ExteNET study on Neratinib in the adjuvant setting as 2nd year treatment following a full year of Herceptin therapy for HER2+ breast cancer. The data indicated 33% and 37% improvement over placebo for the overall and subgroup populations. However, the read out was missing DFS figures required to reach any conclusions on the strength of the results. In addition, in the HERA study that evaluated Herceptin as 2nd year treatment following a 1st full year of the drug, the DFS at 3 years follow up approached 89%. Therefore, Neratinib would have to handily beat that statistic for payors to reimburse the drug after a full year...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details